Business and People News — 8/21
The latest happenings of the past month, all in one place.
People news
MMS announced the growth of its leadership team with the appointment of Kelly J. Hill to Executive Vice President of Global Business Operations and Strategy, and Michelle Gayari to Executive Vice President of Global Operational Excellence and Innovation. The company also announced that Arunima Sen, MD, Director of Pharmacovigilance and Medical Writing (India), has been appointed to the Indian Society of Clinical Research’s Pharmacovigilance Council.
CTMA has appointed Arnaud Marcel as the new Chief Technology Officer.
Calyx announced that Craig M. Mooney joined the company as Vice President of Science and e-Tech Enabled Services.
PHASTAR announced the appointment of Chuck Gelb as Chief Commercial Officer.
Steve Rosenberg has joined uMotif's Board of Directors.
Business news
Imaging Endpoints announced that it has established a new office located in the Vorstaedte District of Basel, Switzerland.
Recognition
THREAD has been awarded Frost & Sullivan’s 2021 Customer Value Leadership Award. Additionally the company has announced that worldwide analyst Everest Group has deemed them a Leader in the DCT sector.
Sensyne Health plc has reached a milestone of access to a combined clinical research, clinical trial, and real world de-identified and anonymized dataset of over 60 million patients.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
